Axogen Announces FDA Approval of Biologics License Application for AVANCE® (Globe Newswire)
UF startup Axogen, Inc., announced that the U.S. Food and Drug Administration has approved the Biologics License Application for AVANCE® (acellular nerve allograft-arwx).
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s investigational gene therapy for Friedreich’s ataxia (FA).
Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PR Newswire)
UF startup Dialectic Therapeutics has begun patient dosing in a clinical trial of its novel therapy for platinum-resistant ovarian cancer, marking a key milestone in its progress toward new treatment options.
Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003 (BioSpace)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP.
Tech Tuesday: University of Florida Lab Showcases How Molecular Motors Can Improve Human Life (WCJB TV20)
In this week’s Tech Tuesday, UF Innovate highlights Myosin Therapeutics, a biomedical company developing myosin inhibitors to treat cancer.
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma (PR Newswire)
UF startup Myosin Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).
With Startup, Researchers Plan To Help Growers Feed More People, Preserve Environment (UF News)
UF startup EZ Ag Innovations, founded by UF researchers Nathan Boyd and Arnold Schumann, is using AI-powered precision-spraying technology to help farmers reduce chemical use, lower costs, and improve sustainability in agriculture.
LightPath Technologies Receives $4.8 Million Purchase Order for Advanced Infrared Camera Systems (PR Newswire)
UF startup LightPath Technologies announced it has received a $4.8 million purchase order with an existing customer related to the supply of advanced infrared camera systems for public safety applications.
iOncologi Secures Foundational U.S. Patent As Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival With Cancer Immunotherapy (Bio Space))
UF startup iOncologi, Inc. announced that USPTO has granted a U.S. patent for a novel method using RNA-based formulations to enhance tumor responsiveness to immune checkpoint inhibitor (ICI) therapy.